CNS Pharmaceuticals regains Nasdaq compliance; subject to one-year monitoring period

CNS Pharmaceuticals, Inc.

Nasdaq letter dated March 31, 2025 confirms regained compliance with $1.00 bid price rule.
Company subject to Mandatory Panel Monitor for one year from letter date.
If noncompliance occurs within monitoring period, no additional cure period allowed; delisting process begins.
Previous reverse stock splits (>250:1 cumulative) disqualified company from standard compliance period.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.